“With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a ...
News-Medical.Net on MSN
Milken Institute and Ann Theodore Foundation fund mTOR inhibitor trial for sarcoidosis
The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a ...
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results